Genetic determinants of drug response in heart failure

Brian D. Lowes, Peter M. Buttrick

Research output: Contribution to journalArticle

Abstract

Heart failure management is complex and costly. Genetic variations that alter drug absorption, metabolism, and receptor-ligand interactions have the potential to modify drug response and safety. Evidence shows that genetic factors interact with numerous heart failure medications, including vasodilators, β blockers, and angiotensin-converting enzyme inhibitors. Technologic advances will soon allow population-based genomewide genetic testing at a reasonable cost. Understanding the genetic factors that influence drug response in heart failure will allow physicians to personalize therapies and optimize response while minimizing serious adverse events.

Original languageEnglish (US)
Pages (from-to)485-490
Number of pages6
JournalCurrent Cardiovascular Risk Reports
Volume2
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Heart Failure
Pharmaceutical Preparations
Genetic Testing
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Ligands
Physicians
Safety
Costs and Cost Analysis
Population
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Genetic determinants of drug response in heart failure. / Lowes, Brian D.; Buttrick, Peter M.

In: Current Cardiovascular Risk Reports, Vol. 2, No. 6, 01.12.2008, p. 485-490.

Research output: Contribution to journalArticle

@article{a02ab498cad54c80b73ad7bbdcc942e3,
title = "Genetic determinants of drug response in heart failure",
abstract = "Heart failure management is complex and costly. Genetic variations that alter drug absorption, metabolism, and receptor-ligand interactions have the potential to modify drug response and safety. Evidence shows that genetic factors interact with numerous heart failure medications, including vasodilators, β blockers, and angiotensin-converting enzyme inhibitors. Technologic advances will soon allow population-based genomewide genetic testing at a reasonable cost. Understanding the genetic factors that influence drug response in heart failure will allow physicians to personalize therapies and optimize response while minimizing serious adverse events.",
author = "Lowes, {Brian D.} and Buttrick, {Peter M.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1007/s12170-008-0085-1",
language = "English (US)",
volume = "2",
pages = "485--490",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - Genetic determinants of drug response in heart failure

AU - Lowes, Brian D.

AU - Buttrick, Peter M.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Heart failure management is complex and costly. Genetic variations that alter drug absorption, metabolism, and receptor-ligand interactions have the potential to modify drug response and safety. Evidence shows that genetic factors interact with numerous heart failure medications, including vasodilators, β blockers, and angiotensin-converting enzyme inhibitors. Technologic advances will soon allow population-based genomewide genetic testing at a reasonable cost. Understanding the genetic factors that influence drug response in heart failure will allow physicians to personalize therapies and optimize response while minimizing serious adverse events.

AB - Heart failure management is complex and costly. Genetic variations that alter drug absorption, metabolism, and receptor-ligand interactions have the potential to modify drug response and safety. Evidence shows that genetic factors interact with numerous heart failure medications, including vasodilators, β blockers, and angiotensin-converting enzyme inhibitors. Technologic advances will soon allow population-based genomewide genetic testing at a reasonable cost. Understanding the genetic factors that influence drug response in heart failure will allow physicians to personalize therapies and optimize response while minimizing serious adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84873503337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873503337&partnerID=8YFLogxK

U2 - 10.1007/s12170-008-0085-1

DO - 10.1007/s12170-008-0085-1

M3 - Article

AN - SCOPUS:84873503337

VL - 2

SP - 485

EP - 490

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 6

ER -